

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上海醫藥集團股份有限公司

Shanghai Pharmaceuticals Holding Co., Ltd.*

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02607)

**CLARIFICATION ANNOUNCEMENT
CORRIGENDUM FOR 2021 ANNUAL RESULTS ANNOUNCEMENT AND 2021 ANNUAL
REPORT**

We refer to the 2021 Annual Results Announcement and 2021 Annual Report of Shanghai Pharmaceuticals Holding Co., Ltd. (the “**Company**”) dated 30 March 2022 and 25 April 2022, respectively.

Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the 2021 Annual Results Announcement and 2021 Annual Report of the Company.

The Company would like to correct the description as published on page 28 of the 2021 Annual Results Announcement and 2021 Annual Report as follows:

I. Before corrigendum

1. 40 varieties with sales revenue exceeding RMB100 million

By following “product-focus” strategy, and taking advantage of “one product, one strategy”, the Company registered 40 varieties with the sales revenue from manufacturing segment exceeding RMB100 million for the year, covering cardiovascular, digestive system, immunometabolic, systemic anti-infective, psycho-neurological and anti-tumor fields.

II. After corrigendum

1. 44 varieties with sales revenue exceeding RMB100 million

By following “product-focus” strategy, and taking advantage of “one product, one strategy”, **the Company registered a total of 44 products for the year including 40 varieties of key products with the sales revenue from manufacturing segment exceeding RMB100 million and 4 varieties of non-key products exceeding RMB100 million.** Covering cardiovascular, digestive system, immunometabolic, systemic anti-infective, psycho-neurological and anti-tumor fields.

Save for the corrections above, other contents of the Company’s 2021 Annual Results Announcement and 2021

Annual Report remain unchanged.

By order of the Board
Shanghai Pharmaceuticals Holding Co., Ltd.*
ZHOU Jun
Chairman

Shanghai, the PRC, 14 June 2022

As at the date of this announcement, the executive Directors of the Company are Mr. CHO Man, Mr. LI Yongzhong and Mr. SHEN Bo, the non-executive Directors are Mr. ZHOU Jun, Mr. GE Dawei and Ms. LI An, and the independent non-executive Directors are Mr. CAI Jiangnan, Mr. HONG Liang, Mr. GU Zhaoyang and Mr. Manson FOK.

** For identification purpose only*